Treatment of cardiovascular and related pathologies

1. A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective amount for treating hypertrophy of a combination of a compound selected from the group consisting of pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, and a therapeutic cardiovascular compound selected from the group consisting of a calcium channel blocker, a β-adrenergic receptor antagonist, a vasodilator, a diuretic, an α-adrenergic receptor antagonist, an antioxidant, and a mixture thereof,

wherein the 3-acylated pyridoxal analogue is a compound of the formula

wherein

R 1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

R 2 is a secondary amino group.

2. The method of claim 1 , wherein the calcium channel blocker is verapamil, diltiazem, nicardipine, nifedipine, amlodipine, felodipine, nimodipine, or bepridil.

3. The method of claim 1 , wherein the compound is administered enterally or parenterally and the therapeutic cardiovascular compound is administered enterally or parenterally.

4. The method of claim 1 , wherein the compound and the therapeutic cardiovascular compound are administered in a single dosage form.

5. The method of claim 1 , wherein the β-adrenergic receptor antagonist is atenolol, propranolol, timolol or metoprolol.

6. The method of claim 1 , wherein the diuretic is furosemide, diuril, amiloride or hydrodiuril.

7. The method of claim 1 , wherein the α-adrenergic receptor antagonist is prazosin, doxazocin or labetolol.

8. The method of claim 1 , wherein the antioxidant is vitamin E, vitamin C or an isoflavone.

9. A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective for treating hypertrophy amount of a combination of an angiotensin converting enzyme inhibitor and a compound selected from the group consisting of pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, wherein the 3-acylated pyridoxal analogue is a compound of the formula

wherein

R 1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

R 2 is a secondary amino group.

10. The method according to claim 9 , wherein the angiotensin converting enzyme inhibitor is captopril, enalapril, lisinopril, benzazpril, fosinopril, quinapril, ramipril, spirapril, imidapril, or moexipril.

11. A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective amount for treating hypertrophy of a combination of a an angiotensin II receptor antagonist and a compound selected from the group consisting of pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, wherein the 3-acylated pyridoxal analogue is a compound of the formula

wherein

R 1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

R 2 is a secondary amino group.

12. The method according to claim 11 , wherein the angiotensin II receptor antagonist is losartan or valsartan.